GSK plc (NYSE:GSK) Shares Acquired by Simmons Bank

Simmons Bank lifted its position in GSK plc (NYSE:GSK) by 3.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 138,714 shares of the pharmaceutical company’s stock after acquiring an additional 4,130 shares during the period. Simmons Bank’s holdings in GSK were worth $5,141,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc lifted its holdings in shares of GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 676 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 647 shares during the period. BKM Wealth Management LLC acquired a new stake in GSK during the 4th quarter worth $32,000. Jones Financial Companies Lllp lifted its holdings in shares of GSK by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares during the period. Finally, Princeton Global Asset Management LLC boosted its stake in shares of GSK by 54.3% in the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock valued at $56,000 after buying an additional 533 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Down 0.0 %

GSK stock traded down $0.02 during midday trading on Wednesday, hitting $44.13. 1,333,596 shares of the stock were exchanged, compared to its average volume of 3,462,294. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The company has a 50 day moving average price of $41.93 and a two-hundred day moving average price of $39.30. The firm has a market cap of $91.46 billion, a P/E ratio of 16.01, a P/E/G ratio of 1.85 and a beta of 0.65. GSK plc has a 1 year low of $33.33 and a 1 year high of $44.33.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.41%. This is a boost from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio is presently 57.61%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GSK. Morgan Stanley assumed coverage on shares of GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.